echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Cell Rep: Metabolic disorders are common in different organs in patients with type 2 diabetes

    Cell Rep: Metabolic disorders are common in different organs in patients with type 2 diabetes

    • Last Update: 2022-10-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      

    The most typical change in patients with type 2 diabetes is insufficient insulin secretion, and different organs are less
    sensitive to insulin.
    To study what happens to these organs when type 2 diabetes occurs, the researchers looked at proteins in insulin-producing insulin-producing islet cells in the pancreas, as well as proteins in the main tissues where insulin acts (i.
    e.
    , liver, skeletal muscle, fat, and blood
    ).

    The researchers compared proteins
    in samples of people with type 2 diabetes, people with prediabetes (i.
    e.
    , the stage before they fully developed type 2 diabetes) and those who did not have diabetes.
    The results showed that metabolic pathways were interfered with much
    more than previously known.
    These changes are also associated with different stages of the
    disease.

    "We detected many protein levels above or below normal in the tissues of patients at different stages of
    the disease.
    Prediabetes patients show major changes
    associated with islet inflammation, blood clotting and the immune system.
    In fully developed type 2 diabetes, there are broader abnormalities, such as lipid and glucose metabolism, as well as energy production of liver, muscle and fat," said
    Professor Claes Wadelius, who coordinated the study.

    The study was based on tissue samples collected from donors and healthy individuals at different stages of the
    disease.
    The samples were collected by EXODIAB, a strategic initiative led by Professor Olle Korsgren of
    Uppsala.

    By using the new technology, researchers can quantify thousands of proteins in each organ, gaining a perspective on
    metabolism that was not previously possible.

    "In recent years, technology for measuring proteins has evolved rapidly, and our colleagues at the University of Copenhagen who were involved in this research are world leaders in this field," said
    Dr.
    Klev Diamanti.
    He conducted the analysis
    in Uppsala with Associate Professors Marco Cavalli and Jan Eriksson.

    Overall, the findings show that metabolism is highly disturbed
    in different pathways at different stages of the organ and disease examined.
    These data point to new underlying causal mechanisms for the disease, which could be further studied to find new ways
    to prevent or treat type 2 diabetes.

    Jan Eriksson, a clinical diabetician, said: "Our findings may also support the development of simple tests that can identify people at high risk for diabetes and its complications and guide which type of intervention is best
    for individuals.
    "

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.